A Multicenter Single-arm Extension Study to Describe the Long-term Efficacy and Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Phase of Trial: Phase III
Latest Information Update: 17 Jun 2019
Price : $35 *
At a glance
- Drugs Etelcalcetide (Primary)
- Indications Secondary hyperparathyroidism
- Focus Adverse reactions; Registrational
- Sponsors Amgen; KAI Pharmaceuticals
- 11 Mar 2019 1-year safety and efficacy results, published in the Nephrology Dialysis Transplantation
- 21 Jul 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 15 May 2015 According to the ClinicalTrials.gov record, planned end date changed from 1 May 2015 to 1 Jul 2015.